Drug intelligence / Profile preview

Hepatitis B antigen peptide

Development stage: Discontinued
Modality: Peptides
Administration: Oral, Intravenous

Overview

Hepatitis B antigen peptide is a protein fragment derived from the Hepatitis B virus surface antigen (HBsAg). It is designed to elicit an immune response against the Hepatitis B virus. This peptide has been investigated as a component in vaccine therapies, including an orally delivered formulation expressed in transgenic potato tubers (HBV-EPV), and as an immunotherapeutic agent when pulsed onto autologous dendritic cells. Its primary function is to act as an antigen to stimulate the body's immune system to recognize and potentially combat Hepatitis B.

Targets

HBc (Hepatitis B virus core protein)preS (Hepatitis B virus preS domain)

Beyond the preview

Go deeper on Hepatitis B antigen peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis B antigen peptide.

Explore the full profile